KRYS vs HALO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
KRYS · Krystal Biotech$308.89 ▼ 2.19%
HALO · Halozyme Therapeutics$91.35 ▼ 1.82%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- KRYS +43.7%
- HALO +23.4%
Head to head
| Metric | KRYS | HALO |
|---|---|---|
| Price | $308.89 | $91.35 |
| Change today | ▼ 2.19% | ▼ 1.82% |
| Market cap | $9.15B | $10.41B |
| Return, 3 months | -9.6% | -15.9% |
| Return, year to date | +25.3% | +35.7% |
| Return, 1 year | +45.7% | +29.9% |
| P/E (TTM) | 42.0 | 22.8 |
| P/B | 6.4 | -188.4 |
| P/E percentile vs own 5y | 68th | 65th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +30.2% | +39.2% |
| Net profit growth (YoY) | -20.5% | +41.0% |
| Gross margin | 94.3% | 82.3% |
| Operating margin | 48.4% | 55.9% |
| Net margin | 47.9% | 26.9% |
| Return on equity | 17.5% | 216.4% |
| Analyst target vs. price | +27.3% | +37.5% |
| Analyst buy share | 100% | 80% |
| RSI (14) | 47 | 20 |
| 30-day volatility | 47.9% | 60.1% |
| Max drawdown, 1 year | -21.8% | -30.4% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HALO is the largest of the group by market value.
- KRYS has returned the most over the past year.
- HALO carries the lowest trailing P/E.
- HALO is growing revenue fastest.
- KRYS keeps the most profit per dollar of sales.
- KRYS has been the calmest stock over the last 30 days.